Business Daily Media

Business Marketing

Eisai: 18-Month, Pre-Specified Analysis Showing Consistent Reduction in Clinical Outcome Measures from a Lecanemab (BAN2401) Phase 2b Clinical Trial in Early Alzheimer's Disease

  • Written by ACN Newswire - Press Releases

Eisai: 18-Month, Pre-Specified Analysis Showing Consistent Reduction in Clinical Outcome Measures from a Lecanemab (BAN2401) Phase 2b Clinical Trial in Early Alzheimer's Disease

TOKYO, Apr 20, 2021 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. today announced the publication of an article, A Randomized, Double-Blind Phase 2b Proof of Concept Clinical Trial in Early Alzheimer's Disease with Lecanemab, an Anti-Abeta Protofibril Antibody, in the peer-reviewed journal Alzheimer's Research and Therapy. The manuscript...

Popular

Mid-Century Furniture for Sale As A Timeless Investment for Your Home Décor

Mid-century furniture for sale is a popular choice among interior design enthusiasts and collectors alike. This style of furniture, which emerged in the mid-20th century, is renowned for its clean lines, bold colours, and innovati...

Adapting to a future in the cloud

Australia is poised to witness a remarkable surge in public cloud services, with Gartner predicting a substantial increase to AU$23.2 billion by 2024—an impressive 19.3% upswing from the previous year. This remarkable surge h...

Vistaprint spotlights Australian small business in new campaign

Vistaprint introduces #VPSupportSmallBusiness - a campaign focused on helping our homegrown business heroes   27 JULY 2020: The impact of coronavirus (COVID-19) is being felt by businesses all around the world. The small b...

Virtual Office
Tomorrow Business Growth